Status:
ENROLLING_BY_INVITATION
Transcranial Direct Current Stimulation Combined With Transcranial Magnetic Stimulation for Motor and Non-Motor Symptoms of Parkinsonian Syndromes
Lead Sponsor:
Second Affiliated Hospital of Soochow University
Conditions:
Parkinsonism
Transcranial Direct Current Stimulation
Eligibility:
All Genders
Phase:
NA
Brief Summary
The combination of transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) is an increasingly recognized neuromodulation strategy in the treatment of Parkinsonian sy...
Detailed Description
Parkinson's disease is a neurodegenerative disorder caused by the degeneration of dopaminergic neurons, with pathological mechanisms involving abnormal activity in neural networks. tDCS modulates the ...
Eligibility Criteria
Inclusion
- ① The diagnosis of primary Parkinson's disease conforms to the clinical diagnostic criteria for PD established by the Movement Disorders Society (MDS) in 2015.
- The diagnosis of Parkinson's plus syndromes conforms to the following: The diagnosis of multiple system atrophy conforms to the clinical diagnostic criteria for MSA established by the MDS in 2022; the diagnosis of progressive supranuclear palsy conforms to the clinical diagnostic criteria for PSP established by the MDS in 2017.
- Having one or more of the following conditions: Complicating with one or more sleep disorders; Complicating with cognitive impairment, with a Mini-Mental State Examination (MMSE) score \< 27 points and/or a Montreal Cognitive Assessment (MoCA) score \< 26 points; Complicating with freezing of gait; Accompanied by one or more types of PD pain, with a Numerical Rating Scale (NRS) score ≥ 3 points and lasting for 3 months or more.
- The medications for treating PD have been stably used for more than 2 weeks, and the original medication treatment regimen is maintained during the transcranial magnetic stimulation (TMS) treatment period.
- Analgesic medications such as non-steroidal anti-inflammatory drugs have been stably used for more than 16 weeks, and the original treatment dosage is maintained unchanged during the trial period.
- ⑥ There is no obvious atrophy and no other characteristic changes in the head CT/MRI examination.
- ⑦ The patient and their family members have been informed of the examination items to be carried out, have given their informed consent, and have signed the informed consent form.
Exclusion
- ① Patients with other diseases that may affect the sensation of peripheral nerves, including diabetes mellitus, herpes infection, long-term use of specific medications or excessive alcohol consumption, stroke, spinal cord lesions, etc.;
- Patients complicated with severe depression or mental disorders;
- Patients with severe cognitive impairment, with a Mini-Mental State Examination (MMSE) score and/or a Montreal Cognitive Assessment (MoCA) score ≤ 9 points; ④ Patients complicated with intracranial organic lesions or craniocerebral trauma; ⑤ Patients complicated with severe organic lesions of the heart, liver, kidney, etc.; ⑥ Patients who cannot complete head MRI examination, transcranial direct current stimulation (tDCS) or transcranial magnetic stimulation (TMS) treatment due to claustrophobia, having implanted devices such as a pacemaker in the body, a history of epilepsy, etc.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07176091
Start Date
January 1 2025
End Date
June 1 2027
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000